Kraig Biocraft Laboratories Reports Increased Net Loss and Rising Operating Expenses for Q1 2026

Kraig Biocraft Laboratories, Inc. reported a net loss of $942,720 for the three months ended March 31, 2026, compared to a net loss of $600,033 for the same period in 2025, marking an increase of 57.1%. The company did not generate any revenue during this period, consistent with the previous year. Total operating expenses rose to $825,500, up 42.2% from $580,492 in the prior year, driven primarily by increased general and administrative costs, professional fees, and research and development expenses. General and administrative expenses alone surged by 60.5% to $495,566, reflecting higher operational costs.

In terms of financial position, Kraig Biocraft Laboratories reported total assets of $3,721,832 as of March 31, 2026, a significant increase from $2,565,540 at the end of 2025. This growth was largely attributed to a rise in cash and cash equivalents, which increased to $2,890,990 from $1,790,236. However, total liabilities also rose to $10,783,506, up from $10,564,498, primarily due to an increase in accounts payable and accrued expenses related to the company's operations. The working capital deficit improved slightly to $7,666,616 from $8,576,604.

Strategically, the company has been focusing on expanding its production capabilities and enhancing its research and development efforts. Kraig Biocraft Laboratories aims to accelerate the commercial-scale production of its recombinant spider silk and plans to develop a line of fashion wear utilizing this technology. The company is also exploring potential acquisitions to broaden its financial base and facilitate product commercialization. As part of its financing strategy, Kraig Biocraft has entered into a Standby Equity Purchase Agreement, allowing it to raise up to $10 million through the sale of common stock.

Operationally, the company has made significant changes, including the dissolution of its subsidiary, Prodigy Textiles Co., Ltd., and the transfer of its production operations to Prodigy Silk Co., Ltd. in Vietnam. This move is part of a broader strategy to streamline operations and enhance efficiency. As of March 31, 2026, Kraig Biocraft Laboratories had a total employee headcount that reflects its ongoing commitment to expanding its workforce in line with its operational goals.

Looking ahead, Kraig Biocraft Laboratories acknowledges the challenges it faces, including the need for additional capital to sustain operations and achieve profitability. The company is actively pursuing funding opportunities and aims to implement its strategic plans to enhance its market position. However, the financial statements raise substantial doubt about the company's ability to continue as a going concern, emphasizing the importance of securing further financing to support its business objectives.